长按二维码,关注官方公众号
QR Code for the Conference Website (Mobile)
Enter the applet sharing event using WeChat scan.
DCAT Week is the premier annual gathering for companies across the global bio/pharmaceutical business ecosystem, held each year in New York City and hosted by the DCAT. It focuses on high-level partnering meetings and strategic networking rather than a traditional exhibition, and is designed to help member companies connect with partners, share insights, and accelerate business development.
Established in 2008, Viva Biotech (01873.HK) provides integrated drug discovery and manufacturing services from early-stage R&D to commercial production. Leveraging expert teams and advanced technology platforms, we support small molecules, biologics, and PPO (peptide, protein, and oligonucleotide) programs. Together with our subsidiary Langhua Pharma and an equity-for-service model, we deliver end-to-end CMC solutions and help accelerate innovative therapies to market.
The Viva Biotech team will be at Hotel 48LEX, Room #404, from March 23-26. We would be delighted to meet with you during this time. Please use the form below to select your preferred experts and schedule a meeting.
Dr. Chen (Cheney) Mao is the Chairman, CEO of our Company. He is primarily responsible for the overall strategic planning and business development of the Group. Dr. Mao has over 20 years of experience in the CRO industry. Dr. Mao obtained his bachelor’s and master’s degree from Fudan University in the PRC, and obtained his Ph.D. degree in biochemistry from Cornell University in the U.S. After graduation, he served as a director of the Department of Structural Biology of Parker Hughes Institute. He also served as a reviewer on the U.S. National Institutes of Health Review Panel ZRG1 AARR-1(50) in relation to AIDS-related structural biology projects grants.
Ph.D. from UT Southwestern Medical Center, Frank and Sara McKnight fellow
Helen Hay Whitney fellow, Harvard Medical School
Scientific Leader & GSK Fellow, GlaxoSmithKline
Senior Director, Johnson & Johsnon
Dr. Susan L. Chen has 20+ years of experience in the peptide and small molecule CRO and CDMO industries. She has rich experience in pharmaceutical drug development, from early phase to late phase, and from research to commercialization, including PRD/ARD, GMP manufacturing, pre-clinical work, clinical development (Phase I–III), operations, regulatory, safety, and commercialization. She has held key positions at several renowned CDMO companies, e.g., AmbioPharm, Sinopep, WuXi STA, and ChemPartner. She earned her Ph.D. degree in Organic Chemistry and Chemical Engineering from the National University of Singapore.
